Dual-tracer PET/CT can ID those who need liver transplant

01/21/2013 | AuntMinnie.com (free registration)

PET/CT imaging using combined carbon-11 acetate and FDG performed better than contrast-enhanced CT in diagnosing hepatocellular carcinoma and staging tumors in liver transplant patients and in partial hepatectomy cases, according to a study in the Journal of Nuclear Medicine. The dual-tracer PET/CT method identified HCC lesions in 94% of liver transplant patients and in 96% of partial hepatectomy patients. In terms of tumor-nodal-metastasis staging, the dual method showed 91% accuracy for the liver transplant group and 90% for the partial hepatectomy group. Overall, the method demonstrated 97% sensitivity and 92% specificity for patient selection for liver transplantation. "The inclusion of dual-tracer PET/CT in pretransplant workup may warrant serious consideration" in improving the determination of patients who are the most in need of a liver transplant, the researchers said.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park